A Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated and Untreated Patients With Chronic Lymphocytic Leukemia.
Phase of Trial: Phase I/II
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Lenalidomide (Primary) ; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors SCRI Development Innovations
- 03 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
- 01 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
- 31 Mar 2016 Primary end points has been modified.